title: Control of a mucosal challenge and prevention of AIDS by a multiprotein     DNA/MVA vaccine.
abstract: Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.
authors.affiliation: Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329, USA.
authors.forename: R R
authors.initials: RR
authors.lastname: Amara
authors.forename: F
authors.initials: F
authors.lastname: Villinger
authors.forename: J D
authors.initials: JD
authors.lastname: Altman
authors.forename: S L
authors.initials: SL
authors.lastname: Lydy
authors.forename: S P
authors.initials: SP
authors.lastname: O'Neil
authors.forename: S I
authors.initials: SI
authors.lastname: Staprans
authors.forename: D C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: Y
authors.initials: Y
authors.lastname: Xu
authors.forename: J G
authors.initials: JG
authors.lastname: Herndon
authors.forename: L S
authors.initials: LS
authors.lastname: Wyatt
authors.forename: M A
authors.initials: MA
authors.lastname: Candido
authors.forename: N L
authors.initials: NL
authors.lastname: Kozyr
authors.forename: P L
authors.initials: PL
authors.lastname: Earl
authors.forename: J M
authors.initials: JM
authors.lastname: Smith
authors.forename: H L
authors.initials: HL
authors.lastname: Ma
authors.forename: B D
authors.initials: BD
authors.lastname: Grimm
authors.forename: M L
authors.initials: ML
authors.lastname: Hulsey
authors.forename: J
authors.initials: J
authors.lastname: Miller
authors.forename: H M
authors.initials: HM
authors.lastname: McClure
authors.forename: J M
authors.initials: JM
authors.lastname: McNicholl
authors.forename: B
authors.initials: B
authors.lastname: Moss
authors.forename: H L
authors.initials: HL
authors.lastname: Robinson
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018858:Germinal Center / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology / Q000502:physiology; D018928:Immunity, Mucosal; D007117:Immunization, Secondary; D007156:Immunologic Memory; D007371:Interferon-gamma / Q000096:biosynthesis; D008198:Lymph Nodes / Q000276:immunology; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014616:Vaccinia virus / Q000276:immunology; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015483:HIV Antibodies; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D007371:Interferon-gamma